In Vitro Treatment of Extracorporeal Membrane Oxygenation Coagulopathy with Recombinant von Willebrand Factor or Lyophilized Platelets
Authors' conclusion
Recombinant vWF and lyophilized platelets may help to restore primary hemostasis in ECMO patients.
Study context
- Population
- Adult ECMO patients and cardiac surgical patients, single academic medical center
- Exposure
- Untreated ECMO samples vs cardiac surgical patients; ECMO samples treated in vitro with recombinant von Willebrand Factor (vWF) or lyophilized platelets vs untreated
- Cardiac surgicaln = 10reference
- ECMO untreatedn = 8
- Outcome
- Maximum force and thrombus area, untreated ECMO vs cardiac surgical
- Follow-up
- 5 minutes
Methodological detailssingle-centre, in vitro treatment
- Single-centre
- In vitro treatment
Main finding
As reported in the abstract
| Group | Value | Thrombus area (median) |
|---|---|---|
| ECMO untreated | median 39.7 nN | 0.05 |
| Cardiac surgical | median 260.2 nN | 0.11 |
Value
ECMO untreatedmedian 39.7 nN
Cardiac surgicalmedian 260.2 nN
Thrombus area (median)
ECMO untreated0.05
Cardiac surgical0.11
- ECMO untreated vs Cardiac surgical: P = 0.008 — maximum force
- ECMO untreated vs Cardiac surgical: P < 0.001 — thrombus area
Observational data: associations, not effects.
Further findings
| Outcome | Recombinant vWF | Lyophilized platelets | P value |
|---|---|---|---|
| Maximum force and thrombus area, recombinant vWF vs untreated ECMOMaximum force | median 222.1 nN | P = 0.01 | |
| Thrombus area (median) | 0.16 | — not stated in the abstract | P = 0.001 |
| Maximum force and thrombus area, lyophilized platelets vs untreated ECMOMaximum force, no increase | median 193.3 nN | P = 0.18 | |
| Thrombus area (median) | — not stated in the abstract | 0.13 | |
| Maximum force and thrombus area, lyophilized platelets vs untreated ECMOThrombus area, significant increase | P = 0.04 |
— not stated in the abstract
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
In Vitro Treatment of Extracorporeal Membrane Oxygenation Coagulopathy with Recombinant von Willebrand Factor or Lyophilized Platelets. J Cardiothorac Vasc Anesth. Published 30 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →